S&P 500   3,120.18 (-0.06%)
DOW   27,934.02 (-0.36%)
QQQ   203.37 (+0.15%)
AAPL   266.29 (-0.30%)
FB   199.32 (+0.97%)
MSFT   150.39 (+0.03%)
GOOGL   1,312.59 (-0.55%)
AMZN   1,752.79 (+0.01%)
CGC   15.32 (+7.74%)
NVDA   207.99 (-2.02%)
MU   46.58 (-2.59%)
BABA   185.25 (+0.35%)
GE   11.50 (+0.52%)
TSLA   359.52 (+2.72%)
T   38.00 (-3.80%)
AMD   41.29 (+3.54%)
ACB   2.34 (+2.63%)
F   8.90 (-0.56%)
PRI   131.64 (+0.41%)
NFLX   302.60 (+0.01%)
BAC   32.94 (-0.06%)
GILD   65.00 (+1.10%)
DIS   148.38 (+0.49%)
S&P 500   3,120.18 (-0.06%)
DOW   27,934.02 (-0.36%)
QQQ   203.37 (+0.15%)
AAPL   266.29 (-0.30%)
FB   199.32 (+0.97%)
MSFT   150.39 (+0.03%)
GOOGL   1,312.59 (-0.55%)
AMZN   1,752.79 (+0.01%)
CGC   15.32 (+7.74%)
NVDA   207.99 (-2.02%)
MU   46.58 (-2.59%)
BABA   185.25 (+0.35%)
GE   11.50 (+0.52%)
TSLA   359.52 (+2.72%)
T   38.00 (-3.80%)
AMD   41.29 (+3.54%)
ACB   2.34 (+2.63%)
F   8.90 (-0.56%)
PRI   131.64 (+0.41%)
NFLX   302.60 (+0.01%)
BAC   32.94 (-0.06%)
GILD   65.00 (+1.10%)
DIS   148.38 (+0.49%)
S&P 500   3,120.18 (-0.06%)
DOW   27,934.02 (-0.36%)
QQQ   203.37 (+0.15%)
AAPL   266.29 (-0.30%)
FB   199.32 (+0.97%)
MSFT   150.39 (+0.03%)
GOOGL   1,312.59 (-0.55%)
AMZN   1,752.79 (+0.01%)
CGC   15.32 (+7.74%)
NVDA   207.99 (-2.02%)
MU   46.58 (-2.59%)
BABA   185.25 (+0.35%)
GE   11.50 (+0.52%)
TSLA   359.52 (+2.72%)
T   38.00 (-3.80%)
AMD   41.29 (+3.54%)
ACB   2.34 (+2.63%)
F   8.90 (-0.56%)
PRI   131.64 (+0.41%)
NFLX   302.60 (+0.01%)
BAC   32.94 (-0.06%)
GILD   65.00 (+1.10%)
DIS   148.38 (+0.49%)
S&P 500   3,120.18 (-0.06%)
DOW   27,934.02 (-0.36%)
QQQ   203.37 (+0.15%)
AAPL   266.29 (-0.30%)
FB   199.32 (+0.97%)
MSFT   150.39 (+0.03%)
GOOGL   1,312.59 (-0.55%)
AMZN   1,752.79 (+0.01%)
CGC   15.32 (+7.74%)
NVDA   207.99 (-2.02%)
MU   46.58 (-2.59%)
BABA   185.25 (+0.35%)
GE   11.50 (+0.52%)
TSLA   359.52 (+2.72%)
T   38.00 (-3.80%)
AMD   41.29 (+3.54%)
ACB   2.34 (+2.63%)
F   8.90 (-0.56%)
PRI   131.64 (+0.41%)
NFLX   302.60 (+0.01%)
BAC   32.94 (-0.06%)
GILD   65.00 (+1.10%)
DIS   148.38 (+0.49%)
Log in

DexCom Stock Price, Forecast & Analysis (NASDAQ:DXCM)

$217.58
+3.80 (+1.78 %)
(As of 11/19/2019 04:00 PM ET)
Today's Range
$212.51
Now: $217.58
$218.93
50-Day Range
$146.08
MA: $165.02
$212.96
52-Week Range
$105.05
Now: $217.58
$218.93
Volume1.26 million shs
Average Volume1.14 million shs
Market Capitalization$19.91 billion
P/E Ratio725.27
Dividend YieldN/A
Beta0.64
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:DXCM
CUSIP25213110
Phone858-200-0200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.03 billion
Cash Flow$0.65 per share
Book Value$7.47 per share

Profitability

Net Income$-127,100,000.00

Miscellaneous

Employees2,800
Market Cap$19.91 billion
Next Earnings Date2/20/2020 (Estimated)
OptionableOptionable

Receive DXCM News and Ratings via Email

Sign-up to receive the latest news and ratings for DXCM and its competitors with MarketBeat's FREE daily newsletter.


DexCom (NASDAQ:DXCM) Frequently Asked Questions

What is DexCom's stock symbol?

DexCom trades on the NASDAQ under the ticker symbol "DXCM."

How were DexCom's earnings last quarter?

DexCom, Inc. (NASDAQ:DXCM) issued its quarterly earnings results on Wednesday, November, 6th. The medical device company reported $0.65 earnings per share for the quarter, topping the consensus estimate of $0.20 by $0.45. The medical device company had revenue of $396.30 million for the quarter, compared to the consensus estimate of $348.99 million. DexCom had a positive return on equity of 16.16% and a negative net margin of 12.68%. The company's revenue for the quarter was up 48.6% on a year-over-year basis. During the same period in the prior year, the business posted $0.17 earnings per share. View DexCom's Earnings History.

When is DexCom's next earnings date?

DexCom is scheduled to release their next quarterly earnings announcement on Thursday, February 20th 2020. View Earnings Estimates for DexCom.

What price target have analysts set for DXCM?

16 analysts have issued twelve-month target prices for DexCom's stock. Their forecasts range from $125.00 to $240.00. On average, they anticipate DexCom's stock price to reach $193.29 in the next year. This suggests that the stock has a possible downside of 11.2%. View Analyst Price Targets for DexCom.

What is the consensus analysts' recommendation for DexCom?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DexCom in the last year. There are currently 4 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for DexCom.

What are Wall Street analysts saying about DexCom stock?

Here are some recent quotes from research analysts about DexCom stock:
  • 1. According to Zacks Investment Research, "Shares of the company have outperformed the industry in a year's time. Strong contributions from the Sensor and Transmitter segments have been key catalysts. Further, solid guidance instills optimism in the stock. The glucose monitoring market presents significant commercial opportunity for DexCom. Opportunities in alternative markets such as the non-intensive diabetes management space, hospital, gestational, pre-diabetes and obesity are likely to provide DexCom a competitive edge in the MedTech space. Meanwhile, cutthroat competition in the market for blood & glucose monitoring devices remains a headwind. With respect to quarterly results, DexCom exited the second quarter on a strong note, wherein both the top and bottom line beat the Zacks Consensus Estimate." (10/25/2019)
  • 2. Northland Securities analysts commented, "We present here a comparative assessment of 2.0 data readouts. Our global view is….we love Dexcom, but believe the story is going to be pressured on all fronts….top-line growth, margins, and market share. If this data is representative of the FDA submission (or part thereof), there is no doubt that Libre 2.0 will get an i" designation." (6/6/2019)

Has DexCom been receiving favorable news coverage?

Headlines about DXCM stock have been trending very negative recently, InfoTrie Sentiment reports. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. DexCom earned a news sentiment score of -3.4 on InfoTrie's scale. They also assigned headlines about the medical device company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the next few days. View News Stories for DexCom.

Are investors shorting DexCom?

DexCom saw a drop in short interest in the month of October. As of October 15th, there was short interest totalling 5,450,000 shares, a drop of 5.7% from the September 15th total of 5,780,000 shares. Based on an average trading volume of 840,900 shares, the short-interest ratio is currently 6.5 days. Approximately 6.1% of the shares of the company are short sold. View DexCom's Current Options Chain.

Who are some of DexCom's key competitors?

What other stocks do shareholders of DexCom own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DexCom investors own include NVIDIA (NVDA), Alibaba Group (BABA), Netflix (NFLX), salesforce.com (CRM), Paypal (PYPL), Tandem Diabetes Care (TNDM), Micron Technology (MU), ServiceNow (NOW), Adobe (ADBE) and AbbVie (ABBV).

Who are DexCom's key executives?

DexCom's management team includes the folowing people:
  • Mr. Kevin R. Sayer, Exec. Chairman, CEO & Pres (Age 61)
  • Mr. Quentin S. Blackford, Exec. VP & CFO (Age 40)
  • Mr. Steven R. Pacelli, Exec. VP of Strategy & Corp. Devel. (Age 47)
  • Mr. Andrew K. Balo, Exec. VP of Clinical Affairs, Regulatory Strategies & Global Access (Age 71)
  • Mr. Richard B. Doubleday, Exec. VP & Chief Commercial Officer (Age 56)

Who are DexCom's major shareholders?

DexCom's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Columbus Circle Investors (0.54%), Eagle Asset Management Inc. (0.40%), Sumitomo Mitsui Trust Holdings Inc. (0.38%), Stephens Investment Management Group LLC (0.33%), Peregrine Capital Management LLC (0.32%) and First Trust Advisors LP (0.31%). Company insiders that own DexCom stock include Andrew K Balo, Barbara Kahn, Donald Abbey, Eric Topol, Heather S Ace, Jacob Steven Leach, Jay S Skyler, Jeffrey Moy, Kevin R Sayer, Mark G Foletta, Nicholas Augustinos, Patrick Michael Murphy, Quentin S Blackford, Richard Doubleday, Steven R Altman, Steven Robert Pacelli and Terrance H Gregg. View Institutional Ownership Trends for DexCom.

Which institutional investors are selling DexCom stock?

DXCM stock was sold by a variety of institutional investors in the last quarter, including Columbus Circle Investors, Ardevora Asset Management LLP, CWM LLC, Robeco Institutional Asset Management B.V., C WorldWide Group Holding A S, Sumitomo Mitsui Trust Holdings Inc., Virginia Retirement Systems ET AL and SG Americas Securities LLC. Company insiders that have sold DexCom company stock in the last year include Andrew K Balo, Barbara Kahn, Donald Abbey, Heather S Ace, Jacob Steven Leach, Jeffrey Moy, Kevin R Sayer, Mark G Foletta, Nicholas Augustinos, Patrick Michael Murphy, Quentin S Blackford, Richard Doubleday, Steven R Altman and Steven Robert Pacelli. View Insider Buying and Selling for DexCom.

Which institutional investors are buying DexCom stock?

DXCM stock was acquired by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Peregrine Capital Management LLC, State of New Jersey Common Pension Fund D, California Public Employees Retirement System, Lyell Wealth Management LP, Silverleafe Capital Partners LLC, Massachusetts Financial Services Co. MA and Handelsbanken Fonder AB. View Insider Buying and Selling for DexCom.

How do I buy shares of DexCom?

Shares of DXCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is DexCom's stock price today?

One share of DXCM stock can currently be purchased for approximately $217.58.

How big of a company is DexCom?

DexCom has a market capitalization of $19.91 billion and generates $1.03 billion in revenue each year. The medical device company earns $-127,100,000.00 in net income (profit) each year or $0.30 on an earnings per share basis. DexCom employs 2,800 workers across the globe.View Additional Information About DexCom.

What is DexCom's official website?

The official website for DexCom is http://www.dexcom.com/.

How can I contact DexCom?

DexCom's mailing address is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. The medical device company can be reached via phone at 858-200-0200 or via email at [email protected]


MarketBeat Community Rating for DexCom (NASDAQ DXCM)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  785 (Vote Outperform)
Underperform Votes:  463 (Vote Underperform)
Total Votes:  1,248
MarketBeat's community ratings are surveys of what our community members think about DexCom and other stocks. Vote "Outperform" if you believe DXCM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DXCM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel